BR9507452A - Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon - Google Patents

Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon

Info

Publication number
BR9507452A
BR9507452A BR9507452A BR9507452A BR9507452A BR 9507452 A BR9507452 A BR 9507452A BR 9507452 A BR9507452 A BR 9507452A BR 9507452 A BR9507452 A BR 9507452A BR 9507452 A BR9507452 A BR 9507452A
Authority
BR
Brazil
Prior art keywords
interferon polypeptide
standardized antigen
standardized
antigen
pharmaceutical composition
Prior art date
Application number
BR9507452A
Other languages
English (en)
Inventor
Howard L Weiner
Youhai Chen
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of BR9507452A publication Critical patent/BR9507452A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR9507452A 1994-04-08 1995-04-07 Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon BR9507452A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US33252494A 1994-10-31 1994-10-31
PCT/US1995/004512 WO1995027500A1 (en) 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES

Publications (1)

Publication Number Publication Date
BR9507452A true BR9507452A (pt) 1997-08-05

Family

ID=26919544

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9507452A BR9507452A (pt) 1994-04-08 1995-04-07 Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon

Country Status (10)

Country Link
EP (1) EP0752879A4 (pt)
JP (1) JPH09511990A (pt)
KR (1) KR970702067A (pt)
AU (1) AU695883B2 (pt)
BR (1) BR9507452A (pt)
CA (1) CA2187345A1 (pt)
HU (1) HUT76101A (pt)
IL (1) IL113301A0 (pt)
NO (1) NO964200D0 (pt)
WO (1) WO1995027500A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9520118A (sl) * 1994-10-25 1998-08-31 Immulogic Pharmaceutical Corporation Sestavki in zdravljenje multiple skleroze
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US6537810B1 (en) 1996-04-23 2003-03-25 President And Fellows Of Harvard College Methods for regulating T cell subsets by modulating transcription factor activity
AU3825497A (en) * 1996-08-15 1998-03-06 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
EP2301567A1 (en) * 1997-02-28 2011-03-30 Enzo Therapeutics, Inc. Selective immune down regulation (SIDR) for transplantation
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (ja) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド 細胞、神経系−特異的抗原およびそれらの用途
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
EP2295067A1 (en) 2000-05-24 2011-03-16 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services E-selectin for inducing immunotolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2659235A1 (fr) * 1990-03-09 1991-09-13 Asahi Chemical Ind Application du facteur tumoral de necrose au traitement des troubles de demyelinisation, de l'uveite ou des troubles de l'hote qui a recu une greffe.
AU9161591A (en) * 1990-12-19 1992-07-22 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
ATE228373T1 (de) * 1992-02-28 2002-12-15 Autoimmune Inc Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
CA2145863A1 (en) * 1992-10-01 1994-04-28 Martha W. Bond Use of il-10 to prevent or treat insulin-dependent diabetes mellitus
DK0603992T4 (da) * 1992-12-22 2001-03-05 Univ Cincinnati Oral indgivelse af immunologisk aktive biomolekyler og andre terapeutiske proteiner

Also Published As

Publication number Publication date
WO1995027500A1 (en) 1995-10-19
IL113301A0 (en) 1995-07-31
NO964200L (no) 1996-10-03
JPH09511990A (ja) 1997-12-02
EP0752879A4 (en) 1999-07-21
AU2246795A (en) 1995-10-30
KR970702067A (ko) 1997-05-13
EP0752879A1 (en) 1997-01-15
AU695883B2 (en) 1998-08-27
HU9602751D0 (en) 1996-11-28
HUT76101A (en) 1997-06-30
NO964200D0 (no) 1996-10-03
CA2187345A1 (en) 1995-10-19

Similar Documents

Publication Publication Date Title
IL115484A0 (en) Polypeptide derivatives processes for the preparation thereof and pharmaceutical compositions containing the same
IL103910A0 (en) New peptide derivatives and pharmaceutical compositions containing them
IL116512A0 (en) Cyclic peptides their preparation and pharmaceutical compositions containing them
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
HU9802116D0 (en) 19-nor-d-vitamin compounds with biologically effect and pharmaceutical compositions containing them
IL116211A0 (en) Peptide compounds pharmaceutical compositions containing the same and processes for the preparation thereof
IL93090A0 (en) Platinum compounds and pharmaceutical compositions containing the same
IL79235A (en) Pharmaceutical compositions containing solubilized proteins and their preparation
BR1100824A (pt) Composto e composição farmacêutica
IL72799A0 (en) Peptides and pharmaceutical compositions containing them
IL95372A0 (en) Amino acid amides and pharmaceutical compositions containing them
BR9507452A (pt) Composição farmacêutica uso de um polipeptídeo não-interferon uso de uma quantidade de um antígeno padronizado e uma quantidade de um polipeptídeo não-interferon e produto contendo (1) uma quantidade de um antígeno padronizado e (11) uma quantidade de um polipeptídeo não-interferon
AU8923291A (en) L-2'-desoxyuridines and pharmaceutical compositions containing them
IL117349A0 (en) N-(3-benyofuranyl) urea-derivatives their preparation and pharmaceutical compositions containing them
NZ232695A (en) Amino acid derivatives and pharmaceutical compositions thereof
BR9507451A (pt) Composição farmacêutica uso de uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo e produto contendo uma quantidade de (i) um antígeno padronizado em conjunto com uma quantidade de (ii) um polipeptídeo
IT8922164A0 (it) Composizione farmaceutica e procedimento per la sua preparazione
FR2639828B1 (fr) Utilisation du kaempferol et de certains de ses derives pour la preparation d'une composition cosmetique ou pharmaceutique
IL93727A0 (en) Pharmaceutical compositions containing polyoxometallate and certain such compounds
IL113484A0 (en) Viral proteins pharmaceutical compositions containing them their preparation and use
BR9401522A (pt) Aparelho ministrador para ministrar uma quantidade de material viscoso de um recipiente e conjunto de recipiente e aparelho ministrador para ministrar um material viscoso
PT87535A (pt) Process for the preparation of novel anf peptide derivatives and of pharmaceutical compositions containing the same
NZ233082A (en) Amino acid derivatives and pharmaceutical compositions thereof
DK439589D0 (da) Fluorsubstituerede 4'-demethylepipodophyllotoksinderivater samt farmaceutiske praeparater indeholdende samme

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]